Background. Measuring glomerular filtration rate (GFR) is an important assessment in peritoneal dialysis patients. In clinical practice, it is commonly measured by calculating the mean of the urinary clearance of urea and creatinine (GFR UrCl ) but this process is time consuming and unreliable. We wished to compare several estimates of GFR including residual GFR estimated from cystatin C (GFR CysC ) using a published equation (Hoek), GFR UrCl and 51 Crethylenediaminetetraacetic acid (EDTA) clearance, in peritoneal dialysis patients. Methods. GFR CysC , GFR UrCl and 51 Cr-EDTA clearance were measured in 28 patients undergoing peritoneal dialysis in a single dialysis unit. Results. GFR CysC was related to GFR UrCl (Spearman's rank correlation coefficient r s ¼ 0.44; P ¼ 0.0185) and to 51 Cr-EDTA clearance (r s ¼ 0.48; P ¼ 0.0099). GFR CysC values were significantly (P ¼ 0.0077) lower than 51 Cr-EDTA clearance results (mean bias À19.7%). However, GFR CysC did not differ significantly (P > 0.05) from GFR UrCl . Conclusions. GFR CysC is related to GFR UrCl but has a significant negative bias against 51 Cr-EDTA. Given the known limitations of 51 Cr-EDTA in estimating GFR in renal failure, this study provides additional validation suggesting that cystatin C-estimated rGFR (GFR CysC ) gives a reasonable estimation of GFR without the clinical problems associated with 24 h urine collections.
Introduction
Accurate measurements of residual kidney function/glomerular filtration rate (GFR) are important to determine the adequacy of dialysis prescription in peritoneal dialysis patients and are typically estimated by taking the mean of urea and creatinine clearances from a 24 h urine collection (GFR UrCl ). Importantly, this measurement was found to be related to morbidity, mortality and quality of life [1] . However, collecting 24-h urine samples is time consuming, onerous for patients and unreliable. An alternative, simpler and rapid method to assess residual kidney function is clearly desirable.
Cystatin C, a 13 kDa cysteine protease inhibitor, has been proposed as an accurate marker of GFR and has been used to estimate GFR in patients with various degrees of renal impairment [2] [3] [4] . In peritoneal dialysis patients, we have recently shown that serum cystatin C concentration reflects predominantly renal, not peritoneal, clearance [5] and that cystatin C concentrations are correlated with GFR UrCl [5] . A simple formula enabling estimation of residual GFR from cystatin C (GFR CysC ) in dialysis patients has recently been described by Hoek et al. [6] .
In the present study, we have assessed the relationship between GFR CysC and GFR UrCl in peritoneal dialysis patients and provide an independent examination of the performance of the Hoek equation. We also compared GFR CysC against another method of assessing residual kidney function; 51 Cr-ethylenediaminetetraacetic acid (EDTA) clearance. Cr-EDTA clearance ¼ 5 mL/min/1.73 m 2 , serum creatinine ¼ 631 lmol/L) leaving a final study cohort of 28. A full medical history was recorded including primary renal disease. All patients gave informed consent and the study was approved by the research ethics committee.
Materials and methods
GFR UrCl assessment was undertaken 4-6 weeks after commencing peritoneal dialysis. GFR UrCl was calculated from the mean of urea and creatinine clearance in a 24-h urine sample. Blood samples for cystatin C, creatinine and urea were collected contemporaneously. A week later, . Urea and creatinine were measured on a Roche Modular Systems Analyser (Roche Ltd, Basel, Switzerland) in serum and urine using enzymatic methods to avoid problems of interference in creatinine measurement due to the high glucose concentrations. The enzymatic method for creatinine has standardization traceable to isotope dilution mass spectrometry. Serum was also collected simultaneously and stored at À80°C for subsequent cystatin C measurement. Cystatin C was measured using a particle-enhanced nephelometric immunoassay on a BN Prospec System (Siemens, Surrey, UK). The laboratory reference range was 0.53-0.95 mg/L and between-day imprecision was 2.2% at a concentration of 1.8 mg/L. GFR CysC was estimated using the following equation specific for peritoneal dialysis patients: [6] GFR CysC ¼ À0:55 þ 22*ð1=serum cystatin C concentrationÞ All patients in whom GFR CysC was estimated were producing at least 200 mL/24 h urine [6] . In a subsequent analysis, patients with GFR UrCl > 6.5 mL/min/1.73 m 2 (n ¼ 4) were excluded from this estimation as per the original cohort in which the equation was derived [6] .
Relationships between the various estimates of kidney function were studied using Analyse-It statistical package (Analyse-It Software Ltd, Leeds, UK). P <0.05 was considered significant. Most variables did not follow a Gaussian distribution and appropriate non-parametric tests [Spearman rank correlation (r s ) and Wilcoxon's matched-pairs signedranks test] were used. Log-transformed data were used for Bland and Altman bias analyses.
Results
Patient clinical and biochemical characteristics are listed in (Table 1 (Figure 2 ).
Discussion
Several previous studies [6] [7] [8] including our own [5] have considered the relationship between cystatin C concentration and GFR UrCl . To further examine the use of cystatin C as a marker of renal clearance in peritoneal dialysis patients, we used the equation developed by Hoek et al. [6] to generate estimates of GFR derived from serum cystatin C concentration (GFR CysC ) in peritoneal dialysis patients in addition to using an exogenous marker ( 51 Cr-EDTA) to measure GFR. We found no significant difference overall between estimated GFR CysC and measured GFR UrCl , although GFR CysC tended to overestimate GFR UrCl at very low levels of kidney function and vice versa. A similar pattern was observed by Hoek et al. [6] in their original publication. It is difficult to know from this and other studies if GFR CysC or GFR UrCl is a more accurate assessment of true residual GFR. We know that 24-h urine collections are fraught with inaccuracies that may be confounded by the cumulative effect of measurement errors in estimating residual GFR through calculated urea and creatinine clearances (GFR UrCl ). Hence, it is perhaps unsurprising that the strength of the relationship between GFR CysC and GFR UrCl (r s ¼ 0.44) was not strong (but nevertheless the correlation was statistically significant). It is notable that even under our study conditions, three patients failed to accurately complete their GFR UrCl estimation.
We also found that GFR CysC did not correlate with another assessment of GFR ( 51 Cr-EDTA clearance) if we restricted the study to patients that had GFR UrCl 6.5 mL/min/1.73 m 2 . However, when four patients with higher GFR UrCl were included, expanding the range of GFRs studied, the relationship became significant. At the low level of kidney function in our dialysis patients, 51 Cr-EDTA clearance significantly overestimated GFR CysC . There are several possible explanations for the lack of strength of association. It has been suggested that GFR estimations should be based on blood samples obtained 24 h after injection of the exogenous substance when GFR is <15 mL/min [9] , whereas in the present study, the last blood sample was taken 7 h post-injection. There may be individual variation in the production rate and/or extrarenal clearance of cystatin C [10, 11] . A possible further source of variation is the fact that the 51 Cr-EDTA clearance estimation was done a week after samples were collected for cystatin C (and GFR UrCl ) measurement. Furthermore, while plasma clearance techniques using exogenous radioisotopes are known to be reliable in individuals with GFRs >20 mL/min/1.73 m 2 [12] , they are known to significantly overestimate GFR in patients with severe renal insufficiency [12, 13] . By contrast, GFR UrCl measured as described here has been shown to provide a reasonable approximation to true GFR in peritoneal dialysis patients [14] . The most likely interpretation of our data therefore is that 51 Cr-EDTA clearance was overestimating (by 20%) true GFR in our patients, with GFR UrCl and GFR CysC providing a closer approximation to residual kidney function.
The main limitation of our study is the relatively small sample size and the lack of a reference GFR estimation based on urinary clearance of an exogenous marker [12] [13] [14] .
Ideally, the development of cystatin C-based equations for estimating residual GFR (GFR CysC ) should be based on studies incorporating such a reference test. In the absence of an easy to perform and accurate measurement of GFR, it is difficult to show that GFR CysC is more accurate than GFR UrCl in large cohorts of patients. However, the fact that GFR CysC correlates with GFR UrCl would imply that, in our cohort at least, it is a valid and reasonable measurement that was simple to perform in clinical practice.
We have previously shown that cystatin C clearance is predominantly renal and not peritoneal and confirmed in the present study that GFR CysC correlates with GFR UrCl in an independent cohort of peritoneal dialysis patients [5] . Although larger scale studies are required to confirm this, increasing evidence appears to suggest that a single blood test for cystatin C measurement may give simpler and more useful information regarding residual kidney function than complex and cumbersome GFR UrCl measurement. However, a major pillar supporting the use of GFR UrCl in peritoneal dialysis is that it appears to be related to clinically relevant outcomes [1, 15] . Future studies should assess whether residual GFR estimated from cystatin C (GFR CysC ) is equally good (or better) at predicting mortality and peritoneal dialysis technique failure.
